RCN1 induces sorafenib resistance and malignancy in hepatocellular carcinoma by activating c-MYC signaling via the IRE1α–XBP1s pathway

The increasing incidence of hepatocellular carcinoma (HCC) is of great concern globally, but the molecular pathogenesis of these tumors remains unclear. Sorafenib is a first-line drug for the treatment of advanced HCC. However, the efficacy of sorafenib in improving patient survival is limited, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jia-Wei, Ma, Li, Liang, Yuan, Yang, Xiao-Jun, Wei, Song, Peng, Hao, Qiu, Shi-Pei, Lu, Xu, Zhu, Ya-Qing, Wang, Bao-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523720/
https://www.ncbi.nlm.nih.gov/pubmed/34663798
http://dx.doi.org/10.1038/s41420-021-00696-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523720/
https://www.ncbi.nlm.nih.gov/pubmed/34663798
http://dx.doi.org/10.1038/s41420-021-00696-6

Ejemplares similares